CL
Therapeutic Areas
Lisata Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| certepetide (LSTA1) | First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | Phase 2 |
Leadership Team at Lisata Therapeutics
DJ
David J. Mazzo, PhD
President and Chief Executive Officer
KK
Kristen K. Buck, MD
Executive Vice President of R&D and Chief Medical Officer
GS
Gregory S. Berkin
Chief Information Officer and Data Protection Officer
JD
John D. Menditto
Vice President, Investor Relations and Corporate Communications
JN
James Nisco
Senior Vice President, Finance and Treasury and Chief Accounting Officer
WK
William K. Sietsema, PhD
Vice President, Global Regulatory Affairs
RQ
Ryan Quick
Vice President, Chemistry, Manufacturing and Controls
TI
Tariq Imam
Senior Vice President, Business Development and Operations and General Counsel
GB
Gregory B. Brown, MD
Chairman of the Board
SM
Steven M. Klosk
Director